Polymorphisms of p53 and p21 genes in chronic obstructive pulmonary disease

Journal of Laboratory and Clinical Medicine

Volumn 147, Issue 5, 2006, Pages 228-233

  Lee, Yao Ling ^a   Chen, Wei ^b   Tsai, Wen Kai ^b   Lee, Jen Chih ^b   Chiou, Hui Ling ^a   Shih, Chuen Ming ^a,b   Wang, Yi Ching ^c  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GENOMIC DNA; PROLINE; PROTEIN P21; PROTEIN P53; SERINE;

ADULT; AGED; ARTICLE; CALCULATION; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CODON; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ASSOCIATION; DNA ISOLATION; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PERIPHERAL LYMPHOCYTE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STATISTICAL SIGNIFICANCE; TAIWAN;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTO-ONCOGENE PROTEINS P21(RAS); PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; TAIWAN;

EID: 33646363561     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lab.2005.12.008     Document Type: Article

References (33)

1. Pauwels R.A., and Rabe K.F. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 364 (2004) 613-620
2. Sandford A.J., and Silverman E.K. Chronic obstructive pulmonary disease. 1: Susceptibility factors for COPD the genotype-environment interaction. Thorax 57 (2002) 736-741
3. Sandford A.J., Joos L., and Pare P.D. Genetic risk factors for chronic obstructive pulmonary disease. Curr Opin Pulm Med 8 (2002) 87-94
4. Joos L. COPD and genetics-what's new?. Swiss Med Wkly 134 (2004) 437-439
5. Joos L., Pare P.D., and Sandford A.J. Genetic risk factors of chronic obstructive pulmonary disease. Swiss Med Wkly 132 (2002) 27-37
6. Di S.A., Caramori G., Ricciardolo F.L., Capelli A., Adcock I.M., and Donner C.F. Cellular and molecular mechanisms in chronic obstructive pulmonary disease. an overview. Clin Exp Allergy 34 (2004) 1156-1167
7. Clayton S.J., Scott F.M., Walker J., Callaghan K., Haque K., Liloglou T., et al. K-ras point mutation detection in lung cancer. comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification. Clin Chem 46 (2000) 1929-1938
8. Lazarus P., Sheikh S.N., Ren Q., Schantz S.P., Stern J.C., Richie J.P., et al. p53, but not p16 mutations in oral squamous cell carcinomas are associated with specific CYP1A1 and GSTM1 polymorphic genotypes and patient tobacco use. Carcinogenesis 19 (1998) 509-514
9. Franklin W.A., Gazdar A.F., Haney J., Wistuba I.I., La Rosa F.G., Kennedy T., et al. Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest 100 (1997) 2133-2137
10. Tao Q., Zhang Z., and Xu Y. [Apoptosis versus proliferation activities and relative mechanism in chronic obstructive pulmonary disease]. Zhonghua Yi Xue Za Zhi 78 (1998) 574-577
11. Weston A., Ling-Cawley H.M., Caporaso N.E., Bowman E.D., Hoover R.N., Trump B.F., et al. Determination of the allelic frequencies of an L-myc and a p53 polymorphism in human lung cancer. Carcinogenesis 15 (1994) 583-587
12. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 152 (1995) S77-S121
13. Wang Y.C., Chen C.Y., Chen S.K., Chang Y.Y., and Lin P. p53 codon 72 polymorphism in Taiwanese lung cancer patients. association with lung cancer susceptibility and prognosis. Clin Cancer Res 5 (1999) 129-134
14. Shih C.M., Lin P.T., Wang H.C., Huang W.C., and Wang Y.C. Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J Cancer Res 91 (2000) 9-15
15. George D.L. Chronic obstructive pulmonary disease treatment options. J Manag Care Pharm 10 (2004) S11-S16
16. Smith O.O., and Helms P.J. Genetic/environmental determinants of adult chronic obstructive pulmonary disease and possible links with childhood wheezing. Paediatr Respir Rev 2 (2001) 178-183
17. Canman C.E., Gilmer T.M., Coutts S.B., and Kastan M.B. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev 9 (1995) 600-611
18. Canman C.E., Wolff A.C., Chen C.Y., Fornace Jr. A.J., and Kastan M.B. The p53-dependent G1 cell cycle checkpoint pathway and ataxia-telangiectasia. Cancer Res 54 (1994) 5054-5058
19. Xiong Y., Hannon G.J., Zhang H., Casso D., Kobayashi R., and Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366 (1993) 701-704
20. Waga S., Li R., and Stillman B. p53-induced p21 controls DNA replication. Leukemia 11 suppl 3 (1997) 321-323
21. Waga S., Hannon G.J., Beach D., and Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369 (1994) 574-578
22. Murata M., Tagawa M., Kimura H., Kakisawa K., Shirasawa H., and Fujisawa T. Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients. Int J Oncol 12 (1998) 577-581
23. Harris C.C. Structure and function of the p53 tumor suppressor gene. clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88 (1996) 1442-1455
24. Harris C.C. p53 tumor suppressor gene. from the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis 17 (1996) 1187-1198
25. Terry L.A., Boyd J., Alcorta D., Lyon T., Solomon G., Hannon G., et al. Mutational analysis of the p21/WAF1/CIP1/SDI1 coding region in human tumor cell lines. Mol Carcinogen 16 (1996) 221-228
26. Chedid M., Michieli P., Lengel C., Huppi K., and Givol D. A single nucleotide substitution at codon 31 (Ser/Arg) defines a polymorphism in a highly conserved region of the p53-inducible gene WAF1/CIP1. Oncogene 9 (1994) 3021-3024
27. Tsai F.J., Lin H.J., Chen W.C., Tsai C.H., and Tsai S.W. A codon 31 ser-arg polymorphism of the WAF-1/CIP-1/p21/tumour suppressor gene in Chinese primary open-angle glaucoma. Acta Ophthalmol Scand 82 (2004) 76-80
28. Shimizu T., Miwa W., Nakamori S., Ishikawa O., Konishi Y., and Sekiya T. Absence of a mutation of the p21/WAF1 gene in human lung and pancreatic cancers. Jpn J Cancer Res 87 (1996) 275-278
29. Shih C.M., Lin P.T., Wang H.C., Huang W.C., and Wang Y.C. Lack of evidence of association of p21WAF1/CIP1 polymorphism with lung cancer susceptibility and prognosis in Taiwan. Jpn J Cancer Res 91 (2000) 9-15
30. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (1993) 817-825
31. el-Deiry W.S. p21/p53, cellular growth control and genomic integrity. Curr Top Microbiol Immunol 227 (1998) 121-137
32. Zeng Y.X., and el-Deiry W.S. Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene 12 (1996) 1557-1564
33. Tao Q., Zhang Z., and Xu Y. Apoptosis versus proliferation activities and relative mechanism in chronic obstructive pulmonary disease. Zhonghua Yi Xue Za Zhi 78 (1998) 574-577